Podbit · TED Talks Daily
GLP-1s blunt the dopamine spikes triggered by cocaine, alcohol, and other addictive substances — but they don't drain dopamine entirely. Mice given GLP-1s and cocaine had smaller dopamine surges but maintained baseline neurotransmitter levels. The drugs moderate without eliminating the will to live.
Where this was said
At 9:22 · chapter starts 5:29
The centerpiece of the episode, Khullar's TED Talk opens with Mary — a patient who had failed rehab, AA, and Antabuse before enrolling in an Ozempic clinical trial and achieving sobriety [1] — Dhruv Khullar "Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the cravin…" 05:29 . From there, Khullar unfolds the drug's origin story: discovered in the 1980s but unworkable until a Gila monster researcher found a peptide in lizard venom that lasted hours rather than minutes. That discovery unlocked a class of drugs now showing effects far beyond digestion — specifically in the brain's mesolimbic reward pathway. GLP-1s appear to blunt dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. One neuroscientist told Khullar this suggests addiction may have a single universal pathology. But Khullar urges caution: these 'moderation molecules' can become desire dampeners, and anhedonia is a real risk. He closes by invoking Aristotle — and then dismantling him: Aristotle never faced Doritos, TikTok, or fentanyl. Moderation today isn't just a virtue; it is, the science suggests, a physiological state [2] — Dhruv Khullar "GLP-1s suggest that Aristotle's moderation, it's not just a virtue, it is a physiological state. It isn't just about character, it is about…" 14:44 .
Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the craving was gone. She stopped drinking, lost 55 pounds, ended a bad relationship, and started exercising. GLP-1s didn't just treat her addiction; they gave her room to rebuild her life.
GLP-1 was discovered in the 1980s, but it broke down in minutes — useless as a drug. The breakthrough came from an unexpected place: Gila monster venom, which contained a similar peptide that could persist for hours. That discovery launched one of the most consequential drug classes in modern medicine.
GLP-1 (glucagon-like peptide 1) was first discovered in the 1980s and initially studied for diabetes management.
A scientist studying Gila monsters discovered the lizard's venom contained a GLP-1-like peptide that could persist for hours, catalyzing the GLP-1 drug revolution.
GLP-1s don't just reduce appetite — they appear to dampen dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. A neuroscientist told Khullar this suggests addiction has a single universal pathology, and GLP-1s may be part of how we fix it.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
When you vividly imagine something, your visual, auditory, and motor cortices light up almost identically to when it actually happens. This means daily visualization is genuine neural training — not wishful thinking.
Reality has gaps — and you fill them with stories. When you meet someone new and instantly form an impression, that's not perception, it's imagination. Recognizing this is the first step to changing the story.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.